Single-cell technologies in mRNA cancer vaccines
The fast evolution of mRNA-based cancer therapeutics requires advanced frameworks to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor immune microenvironment. In this context, single-cell technologies enable characterization of immune cell subsets, intercellular communication, and therapy resistance drivers. The shift to single-cell profiling provides a transition toward the development of precision mRNA treatments tailored to the unique dynamics of an individual tumor.
Authors
- М. Р. Патышева (ORCID: https://orcid.org/0000-0003-2865-7576)
- А. А. Ибрагимова (ORCID: https://orcid.org/0009-0003-1728-0723)
- Kirill M. Kirilenko
- Ekaterina V. Ovcharenko
- Evgeny V. Denisov
Institutions
- Peoples' Friendship University of Russia (RU)
- Russian Academy of Sciences (RU)
- Tomsk National Research Medical Center (RU)
Publication Details
- Journal
- npj Vaccines
- Published
- 2026-07-18
- DOI
- https://doi.org/10.1038/s41541-026-01529-2
- Primary Topic
- Single-cell and spatial transcriptomics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Russian Science Foundation